Phase 2, Non Randomized, Open Label Study Of Temsirolimus (CCI-779) In Subjects With Advanced Renal Cell Carcinoma (RCC).
Phase of Trial: Phase II
Latest Information Update: 20 Mar 2013
At a glance
- Drugs Temsirolimus (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 26 Apr 2012 Actual end date (Mar 2012) added as reported by ClinicalTrials.gov.
- 26 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 Aug 2011 Planned end date changed from Jul 2011 to Jun 2012 as reported by ClinicalTrials.gov.